Digitisation | June 22, 2022
Iktos and Zealand Pharma to develop AI technology for peptide drug design
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
